Dabigatran: Difference between revisions
From SEHK Wiki
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
'''Dabigatran (PRADAXA)'''（中文：[[達比加群]]） | '''Dabigatran (PRADAXA)'''（中文：[[達比加群]]） | ||
==Common Strengths of Dabigatran== | |||
Dabigatran are available in the following strengths: | |||
75 mg, 110 mg, and 150 mg capsules | |||
==Drug Trade Names of Dabigatran== | |||
Pradaxa | |||
==Drug Usage== | |||
*Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation | |||
*Treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) | |||
*Prevention of blood clots after hip or knee replacement surgery | |||
==Mechanism of Action== | |||
Directly inhibits thrombin, preventing blood clot formation | |||
==Route of Administration== | |||
Oral | |||
Dosages | |||
*For atrial fibrillation: 150 mg twice daily | |||
Renal dose based on eGFR: | |||
*eGFR >50 mL/min: No dosage adjustment required, standard dose of 150 mg twice daily | |||
*eGFR 30-50 mL/min: | |||
**75 mg twice daily for stroke prevention in atrial fibrillation | |||
**150 mg twice daily for treatment of DVT/PE, but use with caution | |||
*eGFR 15-30 mL/min: 75 mg twice daily for stroke prevention in atrial fibrillation | |||
==Side Effects== | |||
{| class="wikitable" | |||
!style="text-align: left"| Frequency | |||
!Adverse reactions | |||
|- | |||
| rowspan="5" | '''Common | |||
| Indigestion | |||
|- | |||
| Heartburn | |||
|- | |||
| Abdominal pain | |||
|- | |||
| Diarrhea | |||
|- | |||
| Minor bleeding | |||
| rowspan="4" | '''Uncommon | |||
| Nausea, vomiting | |||
|- | |||
| Severe heartburn | |||
|- | |||
| Bleeding | |||
|- | |||
| Intracranial hemorrhage | |||
|} | |||
==Pharmacokinetics== | |||
*Absorption | |||
**Peak plasma time 1 - 2 hours | |||
*Metabolism | |||
**Converted to active form dabigatran | |||
*Elimination | |||
**Primarily renal (80%) | |||
*Half-life | |||
**12 to 17 hours | |||
*Drug duration | |||
**12 to 17 hours | |||
==Drug Precautions== | |||
'''Pregnancy | |||
Not recommended | |||
'''Breastfeeding | |||
Not recommended | |||
'''Children and Elderly | |||
*Children: Safety and efficacy not established | |||
*Elderly: Increased risk of bleeding | |||
'''Monitoring Requirements | |||
Renal function, signs of bleeding | |||
'''Drug interactions | |||
P-gp inhibitors, anticoagulants, NSAIDs, antiplatelet drugs | |||
'''Caution | |||
*Use with caution in the elderly and in patients with low body weight | |||
*Use with caution in patients with bleeding disorders, gastritis, and oesophageal reflux | |||
==FAQ== | |||
'''How Should I Take the Tablet? | |||
Swallow capsules whole with water, with or without food. Do not open, break, or chew the capsules | |||
'''What Should I Avoid While Taking? | |||
Activities that increase the risk of bleeding or injury | |||
'''What Happens if I Miss a Dose? | |||
Take as soon as remembered if more than 6 hours until the next dose. If less than 6 hours, skip the missed dose and take the next scheduled dose. | |||
Revision as of 00:02, 8 July 2024
Drug class: Direct Thrombin Inhibitor
Dabigatran (PRADAXA)（中文：達比加群）
Common Strengths of Dabigatran
Dabigatran are available in the following strengths: 75 mg, 110 mg, and 150 mg capsules
Drug Trade Names of Dabigatran
Pradaxa
Drug Usage
- Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
- Treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE)
- Prevention of blood clots after hip or knee replacement surgery
Mechanism of Action
Directly inhibits thrombin, preventing blood clot formation
Route of Administration
Oral
Dosages
- For atrial fibrillation: 150 mg twice daily
Renal dose based on eGFR:
- eGFR >50 mL/min: No dosage adjustment required, standard dose of 150 mg twice daily
- eGFR 30-50 mL/min:
- 75 mg twice daily for stroke prevention in atrial fibrillation
- 150 mg twice daily for treatment of DVT/PE, but use with caution
- eGFR 15-30 mL/min: 75 mg twice daily for stroke prevention in atrial fibrillation
Side Effects
| Frequency | Adverse reactions | |
|---|---|---|
| Common | Indigestion | |
| Heartburn | ||
| Abdominal pain | ||
| Diarrhea | ||
| Minor bleeding | Uncommon | Nausea, vomiting |
| Severe heartburn | ||
| Bleeding | ||
| Intracranial hemorrhage |
Pharmacokinetics
- Absorption
- Peak plasma time 1 - 2 hours
- Metabolism
- Converted to active form dabigatran
- Elimination
- Primarily renal (80%)
- Half-life
- 12 to 17 hours
- Drug duration
- 12 to 17 hours
Drug Precautions
Pregnancy
Not recommended
Breastfeeding
Not recommended
Children and Elderly
- Children: Safety and efficacy not established
- Elderly: Increased risk of bleeding
Monitoring Requirements
Renal function, signs of bleeding
Drug interactions
P-gp inhibitors, anticoagulants, NSAIDs, antiplatelet drugs
Caution
- Use with caution in the elderly and in patients with low body weight
- Use with caution in patients with bleeding disorders, gastritis, and oesophageal reflux
FAQ
How Should I Take the Tablet?
Swallow capsules whole with water, with or without food. Do not open, break, or chew the capsules
What Should I Avoid While Taking?
Activities that increase the risk of bleeding or injury
What Happens if I Miss a Dose?
Take as soon as remembered if more than 6 hours until the next dose. If less than 6 hours, skip the missed dose and take the next scheduled dose.
